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Abstract
Background: Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic
respiratory tract infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents,
including a variety of β-lactam antibiotics, is frequently observed in Bcc strains. Resistance to β-lactams is most
commonly mediated by efflux pumps, alterations in penicillin-binding proteins or the expression of β-lactamases.
β-lactamase inhibitors are able to restore the in vitro activity of β-lactam molecules against a variety of Gram-negative
species, but the effect of these inhibitors on the activity of β-lactam treatment against Bcc species is still poorly
investigated.
Methods: In the present study, the susceptibility of a panel of Bcc strains was determined towards the β-lactam
antibiotics ceftazidime, meropenem, amoxicillin, cefoxitin, cefepime and aztreonam; alone or in combination with
a β-lactamase inhibitor (clavulanic acid, sulbactam, tazobactam and avibactam). Consequently, β-lactamase activity
was determined for active β-lactam/β-lactamase inhibitor combinations.
Results: Clavulanic acid had no effect on minimum inhibitory concentrations, but addition of sulbactam, tazobactam
or avibactam to ceftazidime, amoxicillin, cefoxitin, cefepime or aztreonam leads to increased susceptibility (at
least 4-fold MIC-decrease) in some Bcc strains. The effect of β-lactamase inhibitors on β-lactamase activity is
both strain- and/or antibiotic-dependent, and other mechanisms of β-lactam resistance (besides production of
β-lactamases) appear to be important.
Conclusions: Considerable differences in susceptibility of Bcc strains to β-lactam antibiotics were observed.
Results obtained in the present study suggest that resistance of Bcc strains against β-lactam antibiotics is
mediated by both β-lactamases and non-β-lactamase-mediated resistance mechanisms.
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Background
Infections caused by antibiotic-resistant bacteria pose an
increasing threat to public health, both in terms of hu-
man suffering and in economic terms. In addition to the
costs associated with an extended hospital stay, the costs
for treating infections caused by multidrug-resistant or-
ganisms are much higher than the costs for treating
similar infections caused by sensitive organisms [1]. Des-
pite the impact of these infections, the number of novel
antibiotics in the pipeline is small. This is partly due to
the high costs and extensive research-time associated
with the development of a new antibiotic [2].
The Burkholderia cepacia complex (Bcc) is a group of 20
closely related opportunistic, Gram-negative pathogens [3].
Bcc species are an important cause of severe chronic re-
spiratory infections in patients with cystic fibrosis (CF) [4].
Bcc infection in CF patients often correlates with a rapid
decrease in lung function leading to a poorer prognosis,
longer hospital stays and an increased risk of death. The
ability of Bcc strains to form biofilms in vitro and in vivo
contributes to reduced antimicrobial susceptibility, treat-
ment failure and persistent infection [5–7]. Intrinsic resist-
ance to a wide range of antimicrobial agents, including
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aminoglycosides, polymyxin, first and second generation
cephalosporins, carboxypenicillins and other β-lactam anti-
biotics is frequently observed in Bcc strains. Resistance of
Gram-negative microorganisms to β-lactam molecules is
most commonly mediated by inducible or constitutively
expressed β-lactamases, efflux pumps or alterations in
PBPs [8, 9]. β-lactamase was first identified in 1940 as peni-
cillinase in Escherichia coli even before the clinical use of
penicillin, and has since been identified in a variety of other
bacteria, including species of the Bcc [10–13].
β-lactam antibiotics cause cell death by inhibition of
bacterial cell wall synthesis. They do so by binding to
PBPs, resulting in a decreased cross-linking of peptidogly-
can in the cell wall, eventually leading to cell death [8, 14].
The utility of β-lactams has become compromised
through the increasing presence of both chromosomally
and plasmid-encoded β-lactamase enzymes. Two classifi-
cation schemes are currently used, i.e. the Ambler mo-
lecular classification (based on amino acid sequences and
structural similarities) and the Bush-Jacoby-Medeiros
scheme (classification according to functionality or activity
against β-lactam antibiotics) [15]. In the Ambler scheme,
four groups of β-lactamases are recognized; class A
through D. Class A, C and D have a serine active site and
class B enzymes are metallo-β-lactamases (MBLs) that
need Zn2+ as a cofactor for their activity [10, 14]. The
most commonly encountered β-lactamases are class A en-
zymes with TEM and SHV enzymes regularly found in
Gram-negative bacteria (e.g. E. coli and Klebsiella spp.), as
well as CTX-M extended-spectrum β-lactamases (ESBLs)
and Klebsiella pneumoniae carbapenemases (KPCs) which
are now also frequently encountered. Most class A
enzymes can be inhibited with the commercially available
β-lactamase inhibitors clavulanic acid, sulbactam or tazo-
bactam. Class B β-lactamases (MBLs) pose a particular
challenge for medicinal chemists and clinicians because
thus far, none of the available inhibitors can effectively in-
hibit members of this class [16, 17]. Currently, treat-
ment of MBL-producing organisms is limited to
relatively toxic antibiotics (e.g. colistin) and/or antimi-
crobials likely to cause further development of resist-
ance (e.g. tigecycline). EDTA, that functions as a
chelator of divalent cations (including Zn2+), was used
earlier as an active MBL inhibitor but was withdrawn
from the market in 2008 due to toxicity concerns [14,
18]. Class C or AmpC β-lactamases are encoded by genes
on the bacterial chromosome, although the prevalence of
plasmid-mediated AmpC-enzymes is increasing. Only the
novel β-lactamase inhibitor avibactam is able to inhibit
class C enzymes [10, 14]. Finally, class D β-lactamases
(also known as oxacillinases), are active against a broad
range of β-lactam antibiotics. Clavulanic acid, sulbactam
nor tazobactam inhibit these enzymes, but avibactam in-
hibits some class D enzymes [8, 10, 14].
The fact that some β-lactamase inhibitors restore
the in vitro activity of ceftazidime against a variety of
Gram-negative bacteria is known and well-established
[8, 14, 19, 20], but the effect of adding these inhibi-
tors to β-lactam antibiotics is still poorly investigated
for Bcc species. Previous research on this matter led
to contradictory results; Lagacé-Wiens et al. reported
that avibactam does not have the ability to potentiate
ceftazidime against clinical Bcc isolates, but Mushtaq
et al. observed that avibactam does have variable abil-
ity to restore ceftazidime activity against Bcc isolates
from patients with CF [14, 21]. These data suggest
that in these Bcc isolates resistance against ceftazidime is
not only mediated by expression of β-lactamases but is
also due to other resistance mechanisms (efflux pumps or
altered PBPs). In the present study we wanted to validate
this assumptions for a larger research panel; therefore we
systematically investigated the effect of β-lactamase inhibi-
tors (clavulanic acid, sulbactam, tazobactam and the novel
inhibitor avibactam) on the susceptibility of Bcc species
against several β-lactam antibiotics.
Methods
Strains and culture conditions
The following strains were used: B. cepacia LMG 1222
and LMG 18821; Burkholderia multivorans LMG 18822,
LMG 18825, LMG 13010 and LMG 17588; Burkholderia
cenocepacia LMG 16656, LMG 18828, LMG 18829 and
LMG 18830; Burkholderia vietnamiensis LMG 10929
and LMG 18835; Burkholderia ambifaria LMG 19182
and LMG 19467; Burkholderia lata LMG 6992 and R-
9940; Burkholderia stabilis LMG 14294 and LMG
14086; Burkholderia dolosa LMG 18943 and LMG
18941; Burkholderia anthina LMG 20980 and LMG
20983; Burkholderia pyrrocinia LMG 21824; Burkhol-
deria ubonensis LMG 20358 and LMG 24263; Burkhol-
deria latens LMG 24064; Burkholderia arboris LMG
24066 and R-132; Burkholderia seminalis LMG 24067
and LMG 24272; Burkholderia metallica LMG 24068
and R-2712; and Burkholderia contaminans LMG 16227
and R-12710. The biological and geographic origin of
every Bcc strain is presented in Additional file 1. All
strains were obtained from the BCCM/LMG Bacteria
Collection (Ghent, Belgium) or were kindly provided by
Prof. P. Vandamme (Ghent University, Belgium). Two
control strains were included; P. aeruginosa ATCC
27853 and E. coli ATCC 25922, both obtained from the
ATCC collection (Manassas, VA, USA). Bacterial cul-
tures were stored at -80 °C in Microbank vials (Prolab
Diagnostics, Richmond Hill, ON, Canada) and were
subcultured twice on Luria-Bertani agar (LBA; LabM
Limited, Heywood, UK) before use. All cultures were
incubated aerobically at 37 °C.
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Antibiotics and β-lactamase inhibitors
We used several β-lactam antibiotics of different classes
including amoxicillin (AMOX; aminopenicillin), cefoxi-
tin (CFX; 2nd generation cephalosporin), ceftazidime
(CAZ; 3rd generation cephalosporin), cefepime (CFP;
4th generation cephalosporin), meropenem (MEM; car-
bapenem) and aztreonam (AZT; monobactam). The ef-
fect of combining these antibiotics with the β-lactamase
inhibitors clavulanic acid (CLA), sulbactam (SUL), tazo-
bactam (TAZ) and avibactam (AVI) was investigated.
AMOX, CFX, CAZ, CFP, CLA, SUL and TAZ were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). MEM
was obtained from Hospira Benelux (Antwerp, Belgium),
AZT from TCI Europe (Zwijndrecht, Belgium) and AVI
was obtained from Adooq Bioscience (Irwin, CA, USA).
The concentration range tested for CAZ and MEM was
0.25 − 128 mg/L. Higher concentrations were tested for
AMOX, CFX, CFP and AZT; between 1 and 512 mg/L
(according to Peeters et al. [4] and CLSI guidelines). The
β-lactamase inhibitors were added at fixed concentra-
tions as mentioned in the European Committee on
Antimicrobial Susceptibility testing (EUCAST) break-
point tables; 2 mg/L for CLA and 4 mg/L for SUL, TAZ
and AVI [22].
MIC determination
Susceptibility of the selected Bcc strains was investigated
by determining minimum inhibitory concentrations
(MICs) (in triplicate) of β-lactam antibiotics in the pres-
ence or absence of β-lactamase inhibitors, according to
the EUCAST broth dilution guidelines using flat-
bottomed 96-well microtitre plates (TPP, Trasadingen,
Switzerland) [23]. Antibiotic solutions were added to the
wells and two-fold dilutions were made. Planktonic cul-
tures were grown overnight in Luria-Bertani broth (LBB;
LabM, Lancashire, UK) at 37 °C. The cultures were then
adjusted with double-concentrated Mueller-Hinton broth
(MHB; Beckton, Dickinson & Company (BD), Erembode-
gem, Belgium) to obtain a final inoculum of 5 x 105 cfu/
ml. Plates were incubated for 24 h at 37 °C and optical
density was determined at 590 nm using an Envision mul-
tilable plate reader (Perkin Elmer, Waltham, MA, USA).
The MIC value is the lowest concentration of the anti-
biotic that completely inhibits bacterial growth [4, 23].
β-lactamase activity assay
We explored differences in β-lactamase activity by using
a β-lactamase activity assay kit (Sigma-Aldrich, St. Louis,
MO, USA). This assay is based on the hydrolysis of the
chromogenic molecule nitrocefin, a non-antimicrobial
cephalosporin, by β-lactamase which leads to the pro-
duction of a colorimetric product. Formation of this
product is monitored by measuring absorbance at 490 nm
in an Envision multilable plate reader; every minute, for
60 to 90 min at 25 °C. The amount of enzyme required to
hydrolyze 1.0 μmol of nitrocefin per minute at pH 7.0 at
25 °C is equal to one unit of β-lactamase [10, 11, 24]. Bac-
terial cultures were grown in 96-well microtitre plates in
the presence or absence of antibiotics. Antibiotics were
added to the microtitre plates at concentrations of ¼ MIC
and the β-lactamase inhibitors SUL, TAZ and AVI were
added at 4 mg/L. Planktonic cultures were grown over-
night in LB broth at 37 °C, then adjusted with double-
concentrated MHB to obtain a final inoculum of 5 x
105 cfu/ml in the 96-well plates. For every condition 10
wells in the same plate were filled and the plates were in-
cubated at 37 °C for 24 h. After incubation, the content of
the 10 wells was collected in a pre-weighed plastic tube
and centrifuged at 10 000 RCF for 10 min. Then, super-
natant was discarded and the pellet was weighed and re-
suspended with 5 μL of β-lactamase assay buffer per mg
sample. Subsequently, samples were sonicated for 5 min,
placed on ice for 5 min and centrifuged at 16 000 RCF at
4 °C for 20 min. 1 – 50 μL of the unknown samples was
added to a clear flat 96-well plate and supplemented with
nitrocefin and buffer to a final volume of 100 μL. Immedi-
ately after addition of nitrocefin, absorbance at 490 nm
was measured in an Envision plate reader.
Results and discussion
MIC determination
For six Bcc strains (B. cepacia LMG 1222, B. multivor-
ans LMG 18822, B. cenocepacia LMG 16656, B. vietna-
miensis LMG 10929, B. ambifaria LMG 19182 and B.
lata LMG 6992) and two control strains (P. aeruginosa
ATCC 27853 and E. coli ATCC 25922) MIC values of all
compounds and combinations were determined (Table 1).
When the MIC value for a given antibiotic decreased 4-
fold or more upon addition of a β-lactamase inhibitor,
the inhibitor was considered to have meaningful activity.
CLA showed no effect in this initial screening and was
not included in further experiments. SUL, TAZ and AVI
did show some effect in the initial screening and these
three inhibitors were tested against a larger Bcc strain
panel (Table 2).
In general, the MICs of each β-lactam antibiotic alone
varied widely; with MIC values of CAZ ranging from
0.25 to >128 mg/L, MEM from 0.25 to 64 mg/L, AMOX
from 8 to >512 mg/L, CFX from 2 to >512 mg/L and of
CFP and AZT ranging from 1 to >512 mg/L. Antibiotic
susceptibility results for Bcc species can be expressed as
susceptible (S) or resistant (R) according to the EUCAST
PK/PD (non-species related) breakpoints [22]. In vitro
activity of CAZ against some Bcc strains was increased
when combined with SUL or AVI; e.g. for B. multivorans
LMG 17588 the MIC for CAZ decreased from 16 mg/L
in the absence of a β-lactamase inhibitor to 2 mg/L in
the presence of SUL. Hence, addition of SUL to CAZ for
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treatment of B. multivorans LMG 17588 induces a shift
from R to S. Also for AMOX and AZT an increased in
vitro activity against some strains was observed, in com-
bination with SUL or AVI. However, only the addition of
SUL to AZT treatment leads to a change from R to S for
a slection of strains (B. anthina LMG 20980, B. multi-
vorans LMG 13010 and B. vietnamiensis LMG 18835).
CFP showed at least 4-fold increased activity against
some Bcc strains when combined with SUL, TAZ or AVI
and especially addition of TAZ and SUL leads to a shift
from R to S for certain Bcc strains. Resistance towards
MEM due to β-lactamases has not yet been observed in
the Bcc and MEM is one of the β-lactam antibiotics with
the best growth-inhibitory activity against Bcc species at
clinically relevant concentrations [4, 25]. We did not ob-
serve altered susceptibility to MEM when it was com-
bined with SUL, TAZ or AVI, confirming that Bcc
strains do not produce β-lactamases that can degrade
MEM. For CFX only one combination with meaningful
activity was observed; MIC of CFX against B. lata LMG
6992 decreased from 32 mg/L in the absence of a β-
lactamase inhibitor to 8 mg/L in the presence of SUL.
Due to the lack of PK/PD breakpoints for CFX, it is un-
clear whether this change is clinically relevant. These re-
sults suggest that for most Bcc strains non-β-lactamase-
mediated resistance to CFX, in the form of efflux pumps,
altered PBPs, and/or reduced permeability, plays a more
important role than β-lactamases in β-lactam resistance.
β-lactamase activity assay
For the Bcc strains for which active β-lactam antibiotic/β-
lactamase inhibitor combinations were identified, we inves-
tigated whether there is a relation between differences in
β-lactamase activity and the altered susceptibility observed
upon addition of a β-lactamase inhibitor. Therefore, a β-
lactamase activity assay was used to measure β-lactamase
activity. Only the combinations which showed at least a 4-
fold MIC decrease upon addition of a β-lactamase inhibitor
were included (i.e. CAZ+ SUL, CAZ+AVI, AMOX+ SUL,
AMOX+AVI, CFX + SUL, CFP + SUL, CFP +TAZ, CFP +
AVI, AZT+ SUL and AZT+AVI).
Differences in β-lactamase activity were explored between
untreated samples, samples treated with a β-lactam anti-
biotic alone and samples treated with β-lactam/β-lactamase
inhibitor combination treatments mentioned above (Fig. 1).
Results of the β-lactamase screening are expressed as rela-
tive β-lactamase activities compared to untreated bacterial
samples. For B. multivorans LMG 18825 (Fig. 1a) the MIC
for CFP decreased from 32 mg/L in the absence of an in-
hibitor to 8 mg/L in the presence of AVI, or to 2 mg/L in
the presence of SUL or TAZ. As expected, treatment with
0.5 mg/L CFP significantly (p < 0.05, n = 5) increased rela-
tive β-lactamase activity to 5.44 and addition of 4 mg/L
SUL significantly (p < 0.05, n = 5) decreased β-lactamase ac-
tivity to 1.43. However, addition of 4 mg/L AVI had no sig-
nificant (p > 0.05, n = 5) influence on β-lactamase activity
(5.99) and addition of TAZ to CFP-treatment caused a sig-
nificant (p < 0.05, n = 5) increase in relative β-lactamase ac-
tivity to 13.64. These data demonstrate that there is no
correlation between measured β-lactamase activity and
MIC, suggesting that non-β-lactamase-mediated resistance
mechanisms play an important role in CFP resistance in B.
multivorans LMG 18825. For B. arboris R-132 (Fig. 1b), the
situation is different. We observed high β-lactamase activity
(7.29) when cells were exposed to CAZ, and a high MIC
for CAZ (128 mg/L). Combination treatment with SUL or
AVI led to a statistically significant (p < 0.05, n = 4) decrease
in β-lactamase activity (1.10 and 3.30, respectively),
Table 1 MICs of six antibiotics (in mg/L); alone or in combination with a β-lactamase inhibitor
Bold values indicate combinations leading to at least 4-fold MIC-reduction upon addition of the β-lactamase inhibitor. Underlined values indicate a shift from
resistant to susceptible upon addition of the β-lactamase inhibitor, according to PK/PD (non-species related) EUCAST breakpoints. [22] “-“represents treatment with
β-lactam antibiotic alone. CAZ ceftazidime, MEM meropenem, AMOX amoxicillin, CFX cefoxitin, CFP cefepime, AZT aztreonam. Cla clavulanic acid, Sul sulbactam,
Taz tazobactam, Avi avibactam
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Table 2 MICs of six antibiotics (in mg/L), alone or in combination with a β-lactamase inhibitor
Bold values indicate combinations leading to at least 4-fold MIC-reduction upon addition of the β-lactamase inhibitor. Underlined values indicate a shift from
resistant to susceptible upon addition of the β-lactamase inhibitor, according to PK/PD (non-species related) EUCAST breakpoints. [22] “-“represents treatment with
β-lactam antibiotic alone. CAZ ceftazidime, MEM meropenem, AMOX amoxicillin, CFX cefoxitin, CFP cefepime, AZT aztreonam. Cla clavulanic acid, Sul sulbactam,
Taz tazobactam, Avi avibactam
Everaert and Coenye Antimicrobial Resistance and Infection Control  (2016) 5:44 Page 5 of 8
associated with an 8-fold MIC decrease for CAZ. These
data suggest that for this Bcc strain β-lactamase is the
major cause of resistance to CAZ. For B. cenocepacia LMG
16656 (Fig. 1c), no differences in MIC-values for CAZ
(MIC = 512 mg/L) or CFP (MIC = 32 mg/L) were observed
upon addition of a β-lactamase inhibitor (SUL, AVI or
TAZ). β-lactamase activity assay results showed that treat-
ment with CAZ or CFP induces β-lactamase activity in this
strain, and that addition of a β-lactamase inhibitor to CAZ-
or CFP-treatment has no significant (p > 0.05, n = 3) influ-
ence on β-lactamase activity. A likely explanation for this is
that 15 of the 21 β-lactamases currently identified in the
genome of B. cenocepacia LMG 16656 belong to the
metallo-β-lactamase protein family [26]. As mentioned, this
class of β-lactamases is not inhibited by any of the currently
available β-lactamase inhibitors. The MIC- and β-lactamase
activity results for B. cenocepacia LMG 16656 confirm that
SUL, AVI or TAZ are not able to effectively inhibit metallo-
β-lactamases and thus have no effect on the resistance of
this strain against β-lactam antibiotics. Susceptibility of B.
vietnamiensis LMG 18835 (Fig. 1d) for CAZ, CFP and
AZT is altered upon addition of SUL; addition of SUL de-
creased the MIC for CAZ from 4 mg/L to 0.25 mg/L, for
CFP from 16 mg/L to 1 mg/L and for AZT from 8 mg/L to
1 mg/L. However, relative β-lactamase activity for all three
β-lactams is significantly increased upon addition of SUL.
We currently have no explanation for these at first sight
contradictory results, but it seems likely that both β-
lactamase dependent and independent mechanisms are in-
volved in β-lactam resistance in this strain. Results for the
other Bcc strains investigated (see Additional file 2) confirm
that for most Bcc strains investigated the influence of a β-
lactamase inhibitor on β-lactamase activity is both strain-
and/or antibiotic-dependent.
Conclusions
There are considerable differences in susceptibility of
Bcc strains to different β-lactam antibiotics. In the
present study we investigated the effect of β-lactamase
inhibitors on the susceptibility of Bcc species against β-
lactam antibiotics. CLA had no effect on this susceptibil-
ity for any of the strains tested, but addition of SUL,
Fig. 1 β-lactamase activity and corresponding MIC values for a selection of Bcc strains tested. Dark grey bars: β-lactamase activity relative to untreated
controls, light grey bars: MIC values (mg/L) for a) B. multivorans LMG 18825, b) B. arboris R-132, c) B. cenocepacia LMG 16656 and d) B. vietnamiensis
LMG 18835. * represents statistically significant differences compared to treatment with the β-lactam antibiotic alone (p < 0.05, n≥ 3)
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TAZ or AVI to CAZ, AMOX, CFX, CFP or AZT leads
to increased susceptibility (at least 4-fold decrease in
MIC) in several Bcc strains. An important fact to take
into account is that up to date, there is no clear evidence
that in vitro susceptibility of Bcc species against a
specific antimicrobial compound is related to clinical
outcome [27].
Investigation of the relation between altered suscepti-
bility upon addition of SUL, TAZ or AVI and differ-
ences in β-lactamase activity was performed with a β-
lactamase activity assay kit. Pronounced differences in
β-lactamase activity after exposure to different β-lactam
antibiotics and β-lactamase inhibitors, as well as be-
tween the Bcc strains tested were observed. Some of
the results observed are in line with our expectations,
confirming that resistance against β-lactam antibiotics
is mediated by expression of β-lactamase enzymes
which can be successfully inhibited in vitro by β-
lactamase inhibitors. However, results obtained with
other strains suggest that non-β-lactamase-mediated
resistance mechanisms to β-lactam antibiotics (likely
including reduced membrane permeability, altered
PBPs and presence of efflux pumps) are also important.
Production of β-lactamases is clearly not the only
mechanism Bcc strains use to survive treatment with
β-lactam antibiotics, and it is therefore questionable
that adding β-lactamase inhibitors to β-lactam therapy
will be a valuable approach to combat Bcc infections.
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